Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and well tolerated in all dose groups. The results…
High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors and ensure the availability of important medicines for…
The Global AMR R&D Hub publishes its first report “The state of public and philanthropic investments in AMR R&D – The 2020 annual report…
The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign. The content is available online and a printed publication will shortly be…
BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii BioVersyshas reached a major milestone by entering clinical…